The landscape continues evolving
Cleara Biotech FOXO4-DRI development status
This narrative review examines current evidence surrounding platelet-rich plasma, mesenchymal stem cell therapies, peptide analogs, and evolving pharmacologic agents in the management of lumbar disc degeneration, with particular emphasis on mobility restoration and rehabilitation integration
Researchers who notice unexpected appearance changes after reconstitution such as cloudiness or changes in clarity may also find our article discussing common causes of cloudy reconstitution behavior helpful for additional context
Timothy Garvey, MD, of the University of Alabama at Birmingham, reviews the latest data on CagriSema and emerging amylin-based therapies presented at the 2026 ADA Scientific Sessions
Linan-Rico A, Ochoa-Cortes F, Beyder A, et al